Literature DB >> 26427796

Epac1 Deficiency Attenuated Vascular Smooth Muscle Cell Migration and Neointimal Formation.

Yuko Kato1, Utako Yokoyama2, Chiharu Yanai1, Rina Ishige1, Daisuke Kurotaki1, Masanari Umemura1, Takayuki Fujita1, Tetsuo Kubota1, Satoshi Okumura1, Masataka Sata1, Tomohiko Tamura1, Yoshihiro Ishikawa2.   

Abstract

OBJECTIVE: Vascular smooth muscle cell (SMC) migration causes neointima, which is related to vascular remodeling after mechanical injury and atherosclerosis development. We previously reported that an exchange protein activated by cAMP (Epac) 1 was upregulated in mouse arterial neointima and promoted SMC migration. In this study, we examined the molecular mechanisms of Epac1-induced SMC migration and the effect of Epac1 deficiency on vascular remodeling in vivo. APPROACH AND
RESULTS: Platelet-derived growth factor-BB promoted a 2-fold increase in SMC migration in a primary culture of aortic SMCs obtained from Epac1(+/+) mice (Epac1(+/+)-ASMCs), whereas there was only a 1.2-fold increase in Epac1(-/-)-ASMCs. The degree of platelet-derived growth factor-BB-induced increase in intracellular Ca(2+) was smaller in Fura2-labeled Epac1(-/-)-ASMCs than in Epac1(+/+)-ASMCs. In Epac1(+/+)-ASMCs, an Epac-selective cAMP analog or platelet-derived growth factor-BB increased lamellipodia accompanied by cofilin dephosphorylation, which is induced by Ca(2+) signaling, whereas these effects were rarely observed in Epac1(-/-)-ASMCs. Furthermore, 4 weeks after femoral artery injury, prominent neointima were formed in Epac1(+/+) mice, whereas neointima formation was significantly attenuated in Epac1(-/-) mice in which dephosphorylation of cofilin was inhibited. The chimeric mice generated by bone marrow cell transplantation from Epac1(+/+) into Epac1(-/-) mice and vice versa demonstrated that the genetic background of vascular tissues, including SMCs rather than of bone marrow-derived cells affected Epac1-mediated neointima formation.
CONCLUSIONS: These data suggest that Epac1 deficiency attenuates neointima formation through, at least in part, inhibition of SMC migration, in which a decrease in Ca(2+) influx and a suppression of cofilin-mediated lamellipodia formation occur.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  arterial injury; intima-media thickness; migration; signal transduction; vascular smooth muscle

Mesh:

Substances:

Year:  2015        PMID: 26427796     DOI: 10.1161/ATVBAHA.115.306534

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  18 in total

Review 1.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

2.  Vitexin exerts cardioprotective effect on chronic myocardial ischemia/reperfusion injury in rats via inhibiting myocardial apoptosis and lipid peroxidation.

Authors:  Xia Che; Xin Wang; Junyan Zhang; Chengfeng Peng; Yilan Zhen; Xu Shao; Gongliang Zhang; Liuyi Dong
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  Epac1 deficiency inhibits basic fibroblast growth factor-mediated vascular smooth muscle cell migration.

Authors:  Yuko Kato; Utako Yokoyama; Takayuki Fujita; Masanari Umemura; Tetsuo Kubota; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2018-08-06       Impact factor: 2.781

Review 4.  Transcription factors regulated by cAMP in smooth muscle of the myometrium at human parturition.

Authors:  Jonathan K H Li; Pei F Lai; Rachel M Tribe; Mark R Johnson
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

5.  Inhibition of Epac1 suppresses mitochondrial fission and reduces neointima formation induced by vascular injury.

Authors:  Hui Wang; William G Robichaux; Ziqing Wang; Fang C Mei; Ming Cai; Guangwei Du; Ju Chen; Xiaodong Cheng
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

Review 6.  The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation.

Authors:  Graeme Barker; Euan Parnell; Boy van Basten; Hanna Buist; David R Adams; Stephen J Yarwood
Journal:  J Cardiovasc Dev Dis       Date:  2017-12-05

Review 7.  Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets.

Authors:  Pingyuan Wang; Zhiqing Liu; Haiying Chen; Na Ye; Xiaodong Cheng; Jia Zhou
Journal:  Bioorg Med Chem Lett       Date:  2017-02-27       Impact factor: 2.823

8.  Vesicle miR-195 derived from Endothelial Cells Inhibits Expression of Serotonin Transporter in Vessel Smooth Muscle Cells.

Authors:  Junzhong Gu; Huiyuan Zhang; Bingyang Ji; Hui Jiang; Tao Zhao; Rongcai Jiang; Zhiren Zhang; Shengjiang Tan; Asif Ahmed; Yuchun Gu
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

9.  Epac1 Restores Normal Insulin Signaling through a Reduction in Inflammatory Cytokines.

Authors:  Elizabeth Curtiss; Youde Jiang; Li Liu; Claire Hawthorne; Jessica Zhang; Jena J Steinle
Journal:  Mediators Inflamm       Date:  2018-07-19       Impact factor: 4.711

10.  Epac activation inhibits IL-6-induced cardiac myocyte dysfunction.

Authors:  Huiling Jin; Takayuki Fujita; Meihua Jin; Reiko Kurotani; Yuko Hidaka; Wenqian Cai; Kenji Suita; Rajesh Prajapati; Chen Liang; Yoshiki Ohnuki; Yasumasa Mototani; Masanari Umemura; Utako Yokoyama; Motohiko Sato; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2016-12-19       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.